Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics (SPRO)
:SPRO
Total Valuation
Spero Therapeutics has a market cap or net worth of $128.45M. The enterprise value is $60.54M.
Market Cap$128.45M
Enterprise Value$60.54M
Share Statistics
Spero Therapeutics has 56,339,294 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding56,339,294
Owned by Insiders8.15%
Owned by Institutions10.56%
Financial Efficiency
Spero Therapeutics’s return on equity (ROE) is -1.49 and return on invested capital (ROIC) is -116.05%.
Return on Equity (ROE)-1.49
Return on Assets (ROA)-0.62
Return on Invested Capital (ROIC)-116.05%
Return on Capital Employed (ROCE)-1.19
Revenue Per Employee1.50M
Profits Per Employee-2.14M
Employee Count32
Asset Turnover0.43
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Spero Therapeutics is ―. Spero Therapeutics’s PEG ratio is 0.00205.
PE Ratio―
PS Ratio1.16
PB Ratio1.21
Price to Fair Value1.21
Price to FCF-2.37
Price to Operating Cash Flow-4.76
PEG Ratio0.00205
Income Statement
In the last 12 months, Spero Therapeutics had revenue of 47.98M and earned -68.57M in profits. Earnings per share was -1.27.
Revenue47.98M
Gross Profit-48.78M
Operating Income-73.36M
Pretax Income-68.57M
Net Income-68.57M
EBITDA-72.48M
Earnings Per Share (EPS)-1.27
Cash Flow
In the last 12 months, operating cash flow was -27.67M and capital expenditures 0.00, giving a free cash flow of -27.67M billion.
Operating Cash Flow-27.67M
Free Cash Flow-27.67M
Free Cash Flow per Share-0.49
Dividends & Yields
Spero Therapeutics pays an annual dividend of $0.015, resulting in a dividend yield of ―
Dividend Per Share$0.015
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.64
52-Week Price Change93.16%
50-Day Moving Average2.30
200-Day Moving Average1.80
Relative Strength Index (RSI)45.62
Average Volume (3m)462.72K
Important Dates
Spero Therapeutics upcoming earnings date is Mar 26, 2026, TBA (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend DateSep 16, 2015
Financial Position
Spero Therapeutics as a current ratio of 2.19, with Debt / Equity ratio of 12.65%
Current Ratio2.19
Quick Ratio2.19
Debt to Market Cap0.00
Net Debt to EBITDA0.67
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Spero Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Spero Therapeutics EV to EBITDA ratio is -0.10, with an EV/FCF ratio of -0.30.
EV to Sales0.15
EV to EBITDA-0.10
EV to Free Cash Flow-0.30
EV to Operating Cash Flow-0.30
Balance Sheet
Spero Therapeutics has $48.62M in cash and marketable securities with $3.35M in debt, giving a net cash position of $45.27M billion.
Cash & Marketable Securities$48.62M
Total Debt$3.35M
Net Cash$45.27M
Net Cash Per Share$0.80
Tangible Book Value Per Share$0.85
Margins
Gross margin is -197.89%, with operating margin of -152.91%, and net profit margin of -142.91%.
Gross Margin-197.89%
Operating Margin-152.91%
Pretax Margin-142.91%
Net Profit Margin-142.91%
EBITDA Margin-151.08%
EBIT Margin-151.08%
Analyst Forecast
The average price target for Spero Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast-67.38%
EPS Growth Forecast-1076.54%